JP2020037533A - Skin external preparation - Google Patents

Skin external preparation Download PDF

Info

Publication number
JP2020037533A
JP2020037533A JP2018165621A JP2018165621A JP2020037533A JP 2020037533 A JP2020037533 A JP 2020037533A JP 2018165621 A JP2018165621 A JP 2018165621A JP 2018165621 A JP2018165621 A JP 2018165621A JP 2020037533 A JP2020037533 A JP 2020037533A
Authority
JP
Japan
Prior art keywords
skin
lactic acid
external preparation
water
added
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018165621A
Other languages
Japanese (ja)
Other versions
JP7130330B2 (en
Inventor
伸幸 宮地
Nobuyuki Miyaji
伸幸 宮地
泰裕 小田
Yasuhiro Oda
泰裕 小田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Noevir Co Ltd
Original Assignee
Noevir Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Noevir Co Ltd filed Critical Noevir Co Ltd
Priority to JP2018165621A priority Critical patent/JP7130330B2/en
Publication of JP2020037533A publication Critical patent/JP2020037533A/en
Application granted granted Critical
Publication of JP7130330B2 publication Critical patent/JP7130330B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Abstract

To provide a skin external preparation that uses dead cells of lactic acid bacteria, oligosaccharides and bittern in combination, thereby improving moisture retention of skin.SOLUTION: A skin external preparation contains the following (A)-(C): (A) dead cells of lactic acid bacteria, (B) oligosaccharides, and (C) bittern.SELECTED DRAWING: Figure 1

Description

本発明は、乳酸菌死菌体とオリゴ糖とニガリを併用してなる皮膚外用剤に関する。   The present invention relates to an external preparation for skin comprising a combination of killed cells of lactic acid bacteria, oligosaccharides and bittern.

乳酸球菌であるEnterococcus faecalis EC-12の菌体、特にその加熱処理死菌体に表皮ブドウ球菌由来のグリセロールの産生および皮膚表皮角化細胞由来の抗菌ペプチドの産生を促進する作用があることが知られている。(特許文献1)
グルコオリゴ糖には皮膚常在菌コントロール剤としての作用と表皮ブドウ球菌が皮膚表面に付着することを促進する作用があることが知られている。(特許文献2)
ニガリを有効成分とする皮膚常在菌の生態系バランス調整剤は有益菌である表皮ブドウ球菌に対しては殺菌作用を示さないことが知られている。(特許文献3)
It is known that the cells of Lactococci Enterococcus faecalis EC-12, especially the heat-killed cells, have the effect of promoting the production of glycerol derived from Staphylococcus epidermidis and the production of antimicrobial peptides derived from skin epidermal keratinocytes. Have been. (Patent Document 1)
It is known that gluco-oligosaccharide has an action as a control agent for bacteria resident on the skin and an action to promote attachment of Staphylococcus epidermidis to the skin surface. (Patent Document 2)
It is known that an ecosystem balance regulator of skin-resident bacteria containing bittern as an active ingredient does not have a bactericidal effect on beneficial bacteria, Staphylococcus epidermidis. (Patent Document 3)

特開2017−101006号公報JP, 2017-101006, A 特開2005−2087号公報JP 2005-2087 A 特開2005−139075号公報JP 2005-139075 A

乳酸菌死菌体は不溶性であり皮膚外用剤に多量に配合することが困難であった。オリゴ糖は多量に配合するとべたつきなど使用感に影響があった。また、ニガリはその効果を発揮するのに多量の配合を必要とすることが報告されている。本発明は、乳酸菌死菌体とオリゴ糖とニガリを併用することにより、皮膚の保湿性が向上する皮膚外用剤を提供することを課題とする。   The killed cells of lactic acid bacteria were insoluble and it was difficult to mix them in a large amount in a skin external preparation. The use of a large amount of oligosaccharides affected the feeling of use such as stickiness. It is also reported that bittern requires a large amount of the compound to exert its effect. An object of the present invention is to provide an external preparation for skin that improves the moisturizing property of the skin by using a killed lactic acid bacterium, an oligosaccharide, and a bittern.

本発明は、
下記(A)〜(C)を含有する皮膚外用剤
(A)乳酸菌死菌体
(B)オリゴ糖
(C)ニガリ
を提供する。
The present invention
A skin external preparation (A) containing killed cells of lactic acid bacteria (B) oligosaccharide (C) bittern containing the following (A) to (C):

本発明の皮膚外用剤は、乳酸菌死菌体とオリゴ糖とニガリを併用して用いることにより、有用な常在菌である表皮ブドウ球菌が増殖し、皮膚の保湿力が相乗的に向上する。   By using the killed lactic acid bacteria, oligosaccharides and bittern in the skin external preparation of the present invention in combination, Staphylococcus epidermidis, a useful resident bacterium, multiplies, and the moisturizing power of the skin is synergistically improved.

図1は、3成分を併用することにより、表皮ブドウ球菌の増殖比が相乗的に向上することを示す図である。FIG. 1 is a diagram showing that the growth ratio of Staphylococcus epidermidis is synergistically improved by using three components in combination. 図2は、3成分を併用することにより、皮表角層水分量が相乗的に向上することを示す図である。FIG. 2: is a figure which shows that a skin horny layer water content improves synergistically by using 3 components together. 図3は、3成分を併用することにより、経表皮水分蒸散量が相乗的に減少することを示す図である。FIG. 3 is a diagram showing that the transepidermal water loss is synergistically reduced by using three components in combination.

以下本発明を実施するための形態を説明する。   Hereinafter, embodiments for carrying out the present invention will be described.

本発明の皮膚外用剤は、化粧品、医薬部外品、医薬品等のいずれの用途にも用いられ得る。   The external preparation for skin of the present invention can be used for any of cosmetics, quasi-drugs, pharmaceuticals and the like.

本発明は、乳酸菌死菌体を必須成分として含む皮膚外用剤である。   The present invention is an external preparation for skin containing dead cells of lactic acid bacteria as an essential component.

前記乳酸菌は、ストレプトコッカス(Streptococcus)属、ラクトコッカス(Lactococcus)属、エンテロコッカス(Enterococcus)属、ラクトバチルス(Lactobacillus)属、ペディオコッカス(Pediococcus)属、リューコノストック(Leuconostoc)属、ワイセラ(Weissella)属及びビフィドバクテリウム(Bifidobacterium)属からなる群より選ばれた一つ以上の菌株であることが好ましい。特にはエンテロコッカス・フェカリス(Enterococcus faecalis)であることが好ましい。 The lactic acid bacteria include Streptococcus, Lactococcus, Enterococcus, Lactobacillus, Pediococcus, Leuconostoc, and Weissella. It is preferably at least one strain selected from the group consisting of the genus and the genus Bifidobacterium. Particularly preferred is Enterococcus faecalis.

乳酸球菌の培養方法としては、従来公知の乳酸菌の培養方法も含め特に制限されるものではないが、加熱処理死菌体は、次の方法によって製造することができる。乳酸球菌を常法にしたがって培養して得られた培養物から、例えば、濾過、遠心分離等の方法により菌体を回収し、水洗後、水等に懸濁して加熱処理した後、必要に応じて濃縮、乾燥することにより調整できる。通常使用される噴霧乾燥、凍結乾燥機等を用いて行ってもよい。場合によっては、加熱等による殺菌処理の前後、あるいは、乾燥処理の前後に、酵素処理、界面活性剤処理、磨砕・粉砕処理を行うこともでき、これらの処理により得られるものも、本発明の死菌体に含まれる。   The method for culturing lactic acid bacterium is not particularly limited, including a conventionally known method for culturing lactic acid bacterium. Heat-killed cells can be produced by the following method. From the culture obtained by culturing the lactic acid bacterium according to a conventional method, for example, the cells are collected by filtration, centrifugation, etc., washed with water, suspended in water, etc., and heat-treated. It can be adjusted by concentrating and drying. It may be carried out using a commonly used spray dryer, freeze dryer or the like. In some cases, before or after sterilization by heating or before or after drying, enzyme treatment, surfactant treatment, grinding and pulverization can also be performed, and those obtained by these treatments can be used in the present invention. Of dead cells.

水洗及び懸濁に使用する水は、純水、水道水、井戸水、鉱泉水、鉱水、温泉水、湧水、淡水等の他、これらに各種処理を施したものが含まれる。水に施す処理としては、例えば、精製、加熱、殺菌、ろ過、イオン交換、浸透圧の調整、緩衝化等が含まれる。従って、本発明において抽出溶媒として使用可能な水には、精製水、加熱処理水、イオン交換水、生理食塩水、種々緩衝液等も含まれる。   The water used for washing and suspension includes pure water, tap water, well water, mineral spring water, mineral water, hot spring water, spring water, fresh water, and the like, as well as those subjected to various treatments. Examples of the treatment applied to water include purification, heating, sterilization, filtration, ion exchange, adjustment of osmotic pressure, buffering, and the like. Therefore, the water that can be used as an extraction solvent in the present invention includes purified water, heat-treated water, ion-exchanged water, physiological saline, various buffers, and the like.

本発明における当該製剤への乳酸菌死菌体の配合量としては、通常0.01〜2質量%、特に0.01〜1質量%が好ましい。   In the present invention, the amount of the killed lactic acid bacteria in the preparation is usually 0.01 to 2% by mass, particularly preferably 0.01 to 1% by mass.

本発明の皮膚外用剤は、オリゴ糖を含有する。オリゴ糖を配合することにより、保湿効果を向上させることができる。   The external preparation for skin of the present invention contains an oligosaccharide. By blending the oligosaccharide, the moisturizing effect can be improved.

本発明に用いるオリゴ糖としては、キシロビオース、キシロトリオース、キシロテトラオース、キシロペンタオース等のキシロオリゴ糖、アガロビオース、カラビオース等のガラクトオリゴ糖類、グルコテトラオース、マルトース、マルトトリオース、マルトテトラオース、マルトペンタオース、イソマルトース、ソホロース、セロビオース、セロトリオース、セロテトラオース、セロペンタオース、トレハロース、ネオトレハロース、イソトレハロース等のグルコオリゴ糖類、マンノオリゴ糖類、イヌロビオース、イヌロトリオース、イヌロテトラオース、イヌロペンタオース等のフルクトオリゴ糖類といったホモオリゴ糖類、ビシアノース、イソプリメベロース、サンブビオース、プリメベロース、リコテトラオース、ソラビオース、メリビオース、マンニノトリオース、ラクトース、リコビオース、リコトリオース、エピセロビオース、スクロース、ツラノース、マルツロース、イソケストース、エルロース、ケストース、ゲンチアノース、ラクツロース、エピゲンチビオース、イソリクノース、ウンベリフェロース、セサモース、ラフィノース、リクノース、ロビノビオース、シラノビオース、ルチノース、カコトリオース、ソラトリオース、グリコシルトレハロース等のヘテロオリゴ糖類が挙げられる。   Examples of the oligosaccharide used in the present invention include xylo-oligosaccharides such as xylobiose, xylotriose, xylotetraose, and xylopentaose, galacto-oligosaccharides such as agarobiose and carabiose, glucotetraose, maltose, maltotriose, maltotetraose, and maltose. Glucooligosaccharides such as pentaose, isomaltose, sophorose, cellobiose, cellotriose, cellotetraose, cellopentaose, trehalose, neotrehalose, and isotrehalose; mannooligosaccharides; inulobiose; inulotriose; inulotetraose; inulotetraose; Homo-oligosaccharides such as fructooligosaccharides, bicyanose, isoprimeverose, sambubiose, primeverose, lycotetraose, sorabiose, Biose, manninotriose, lactose, lycobiose, lycotriose, epicellobiose, sucrose, turanose, maltulose, isokestose, erulose, kestose, gentianose, lactulose, epigentibiose, isorikunose, umbelliferose, sesamorse, raffinose Hetero-oligosaccharides such as robinobiose, silanobiose, rutinose, cacotriose, solatriose, and glycosyltrehalose.

オリゴ糖としてはグルコオリゴ糖が好ましく用いられる。中でもグルコテトラオースが好ましい。グルコテトラオースは、天然の糖であるマルトースとショ糖から固定化酵素法により得られる。例えば、(O−α−D−グルコピラノシル−(1→2))− (O−α−D−グルコピラノシル−(1→6))−(O−α−D− グルコピラノシル−(1→4))−(O−α−D−グルコピラノース)なる構造を有するものが挙げられる。このようなグルコオリゴ糖は、例えば、BIOECOLIA(登録商標:Solabia)として市販されている。   Glucoligosaccharide is preferably used as the oligosaccharide. Among them, glucotetraose is preferred. Glucotetraose is obtained from the natural sugars maltose and sucrose by an immobilized enzyme method. For example, (O-α-D-glucopyranosyl- (1 → 2))-(O-α-D-glucopyranosyl- (1 → 6))-(O-α-D-glucopyranosyl- (1 → 4))- (O-α-D-glucopyranose). Such a gluco-oligosaccharide is commercially available, for example, as BIOECOLIA (registered trademark: Solabia).

本発明における当該製剤へのオリゴ糖の配合量としては、通常0.01〜20質量%、特に0.01〜10質量%が好ましい。   The amount of the oligosaccharide to be added to the preparation in the present invention is usually 0.01 to 20% by mass, particularly preferably 0.01 to 10% by mass.

本発明において用いるニガリは、海水から食塩を製造するにあたり食塩を晶出させた後の液若しくはその乾燥物、若しくは人為的にミネラル分を混合したものを用いる。ニガリの組成は、産地、製塩法(イオン交換膜法、天日法、塩田法若しくは蒸発法)の相違、食塩晶出時の温度、食塩晶出時の食塩濃度及び圧力その他の条件によって変わってくるが、トカラ列島周辺海域、若しくは南大東島周辺海域で採取した海水を原料として調製したニガリは、海水中に含まれる有機リン酸化合物等の汚染物質の混入が無く、高い効果が得られる。   As the bittern used in the present invention, in producing salt from seawater, a liquid obtained by crystallizing salt or a dried product thereof, or a product obtained by artificially mixing a mineral component is used. The composition of bittern varies depending on the locality of production, differences in salt production methods (ion exchange membrane method, solar method, salt field method or evaporation method), temperature during salt crystallization, salt concentration and pressure during salt crystallization and other conditions. However, bittern prepared using seawater collected from the sea area around the Tokara Islands or the sea area around Minami Daito Island has no contamination of contaminants such as organic phosphate compounds contained in the seawater, and a high effect can be obtained.

本発明における当該製剤へのニガリの配合量としては、通常0.0001〜5質量%、特に0.01〜3質量%が好ましい。   The amount of bittern to be added to the preparation in the present invention is usually 0.0001 to 5% by mass, particularly preferably 0.01 to 3% by mass.

本発明の皮膚外用剤には上述の必須成分の他に、必要に応じて通常皮膚外用剤に配合される、水性成分、油性成分、保湿剤、色素、界面活性剤、紫外線吸収剤、増粘剤、美容成分、香料、高分子物質、防菌防微剤、アルコール類、粉体、スクラブ剤、生体由来成分等を適宜配合することができる。   In addition to the above-mentioned essential components, the skin external preparation of the present invention usually contains an aqueous component, an oily component, a humectant, a pigment, a surfactant, an ultraviolet absorber, and a thickener, which are usually added to the skin external preparation as needed. Agents, beauty ingredients, fragrances, polymeric substances, antibacterial and antimicrobial agents, alcohols, powders, scrubbing agents, biological components and the like can be appropriately compounded.

本発明の皮膚外用剤は、例えば、ローション剤、乳剤、軟膏の剤型で用いることができる。また、本発明の皮膚外用剤は、製造方法を問わない。   The external preparation for skin of the present invention can be used, for example, in the form of lotions, emulsions, and ointments. Further, the method for producing the external preparation for skin of the present invention does not matter.

本発明の皮膚外用剤の効果について、以下の通り測定を行った。   The effect of the external preparation for skin of the present invention was measured as follows.

表1に示した組成の実施例並びに比較例を調製し、表皮ブドウ球菌に対する作用を検討した。
[被検物質]
乳酸菌死菌体:ラ・フローラ EC-12(製造元:一丸ファルコス株式会社)を使用した。
オリゴ糖:BIOECOLIA(製造元:Solabia)を使用した。
ニガリ:トカラニガリ N(製造元:ノエビア)を使用した。
[供試菌株]
有益菌として表皮ブドウ球菌(Staphylococcus epidermidis:NBRC No.12993)を採択した。
Examples and comparative examples having the compositions shown in Table 1 were prepared, and their effects on Staphylococcus epidermidis were examined.
[Test substance]
Lactobacilli killed cells: La Flora EC-12 (manufacturer: Ichimaru Falcos Co., Ltd.) was used.
Oligosaccharide: BIOECOLIA (manufacturer: Solabia) was used.
Nigari: Tokara Nigari N (manufacturer: Noevir) was used.
[Test strain]
Staphylococcus epidermidis (NBRC No. 12993) was adopted as a beneficial bacterium.

[表皮ブドウ球菌増殖効果の評価]
96穴マイクロプレートに、普通ブイヨン培地(栄研化学)で所定濃度に希釈した被検物質溶液100μLを投入する。続いてOD650=0.05に調整した表皮ブドウ球菌100μLを滴下した。37℃で6時間振とう培養後、OD650nmで測定し、各菌の生菌数を測定した。比較例4を100とした場合の相対値で細菌に対する増殖効果を評価した。結果を表1に示す。
[Evaluation of Staphylococcus epidermidis multiplication effect]
Into a 96-well microplate, 100 μL of a test substance solution diluted to a predetermined concentration in a normal bouillon medium (Eiken Chemical) is added. Subsequently, 100 μL of Staphylococcus epidermidis adjusted to OD 650 = 0.05 was added dropwise. After shaking culture at 37 ° C. for 6 hours, measurement was performed at OD 650 nm, and the viable cell count of each bacterium was measured. The growth effect on bacteria was evaluated by a relative value when Comparative Example 4 was set to 100. Table 1 shows the results.

[使用試験]
表1に示した組成の実施例並びに比較例を調製し、使用試験を実施した。
27〜44歳の男性3名(平均年齢38歳)を被験者として、皮膚外用剤を1日朝晩2回、前腕部3cm×3cmの領域に9μLを滴下し使用させた。使用前、使用1週間後の、皮表角層水分量及び経表皮水分蒸散量の測定を行った。
[Usage test]
Examples and comparative examples having the compositions shown in Table 1 were prepared, and use tests were performed.
Three males aged 27 to 44 (mean age 38 years) were used as test subjects, and 9 μL of a skin external preparation was dropped and used twice daily in the morning and evening on a 3 cm × 3 cm area of the forearm. Before and one week after use, the water content of the epidermal skin layer and the transepidermal water loss were measured.

[測定方法]
(1)馴化
被験者は前腕部を洗浄後、温度:21℃、湿度:50%にて調整された室内にて15分馴化することで初期条件を整え、測定を行った。
[Measuring method]
(1) Acclimation After cleaning the forearm, the subject was acclimated for 15 minutes in a room conditioned at a temperature of 21 ° C. and a humidity of 50% to prepare initial conditions and measure.

(2)皮表角層水分量
SKICON-200EXを用いて、前腕部5点を測定し、平均値を皮表角層水分量とした。使用試験前の皮表角層水分量を1とした場合の相対値を算出し、表1に示した。
(2) Skin superficial stratum corneum water content Using SKICON-200EX, 5 points of the forearm were measured, and the average value was defined as the skin superficial stratum corneum water content. Relative values were calculated assuming that the water content of the skin surface horny layer before the use test was 1, and the results are shown in Table 1.

(3)経表皮水分蒸散量
Vapometerを用いて、前腕部2点を測定し、平均値を経表皮水分蒸散量とした。使用試験前の経表皮水分蒸散量を1とした場合の相対値を算出し、表1に示した。
(3) Transepidermal Water Evaporation Two points on the forearm were measured using a Vapometer, and the average value was taken as the transepidermal water evaporation. Relative values were calculated assuming that the transepidermal water loss before the use test was 1, and the results are shown in Table 1.

Figure 2020037533
Figure 2020037533

表1に示した通り、3成分を併用して塗布することにより、単独(それぞれの有効成分量は3倍量となる)で塗布した場合と比較して、表皮ブドウ球菌の増殖比が相乗的に向上していた。   As shown in Table 1, the growth ratio of Staphylococcus epidermidis is synergistic by applying the three components in combination, as compared with the case of applying alone (the amount of each active ingredient is tripled). Had improved.

表1に示した通り、3成分を併用して塗布することにより、単独(それぞれの有効成分量は3倍量となる)で塗布した場合と比較して、皮表角層水分量が相乗的に向上していた。   As shown in Table 1, when the three components are applied in combination, the skin surface horny layer water content is synergistic as compared with the case where the three components are applied alone (the amount of each active ingredient is tripled). Had improved.

表1に示した通り、3成分を併用して塗布することにより、単独(それぞれの有効成分量は3倍量となる)で塗布した場合と比較して、経表皮水分蒸散量が相乗的に減少していた。   As shown in Table 1, the transepidermal water loss was synergistically achieved by applying the three components in combination, as compared to the case of applying alone (the amount of each active ingredient was tripled). Had decreased.

[実施例2]乳液
(1)スクワラン 10.0(質量%)
(2)メチルフェニルポリシロキサン 4.0
(3)水素添加パーム核油 0.5
(4)水素添加大豆リン脂質 0.1
(5)モノステアリン酸ポリオキシエチレン
ソルビタン(20E.O.) 1.3
(6)モノステアリン酸ソルビタン 1.0
(7)グリセリン 4.0
(8)パラオキシ安息香酸メチル 0.1
(9)カルボキシビニルポリマー 0.15
(10)精製水 100合わせ
(11)アルギニン(1質量%水溶液) 20.0
(12)乳酸菌死菌体 0.1
(13)オリゴ糖 0.2
(14)ニガリ 0.8
製法:(1)〜(6)の油相成分を80℃にて加熱溶解する。一方(7)〜(10)の水相成分を80℃にて加熱溶解する。これに前記油相成分を攪拌しながら加え、ホモジナイザーにより均一に乳化する。乳化終了後、冷却を開始し、(11)〜(14)を順次加え、均一に混合する。
Example 2 Emulsion (1) Squalane 10.0 (% by mass)
(2) Methylphenyl polysiloxane 4.0
(3) Hydrogenated palm kernel oil 0.5
(4) Hydrogenated soybean phospholipid 0.1
(5) Polyoxyethylene monostearate
Sorbitan (20EO) 1.3
(6) Sorbitan monostearate 1.0
(7) Glycerin 4.0
(8) Methyl paraoxybenzoate 0.1
(9) Carboxyvinyl polymer 0.15
(10) 100 sets of purified water (11) Arginine (1% by mass aqueous solution) 20.0
(12) Dead cells of lactic acid bacteria 0.1
(13) Oligosaccharide 0.2
(14) Nigari 0.8
Production method: The oil phase components (1) to (6) are dissolved by heating at 80 ° C. On the other hand, the aqueous phase components (7) to (10) are heated and dissolved at 80 ° C. The oil phase component is added thereto with stirring, and the mixture is uniformly emulsified by a homogenizer. After the emulsification is completed, cooling is started, and (11) to (14) are sequentially added and uniformly mixed.

[実施例3]化粧水
(1)エタノール 15.0(質量%)
(2)ポリオキシエチレン(40E.O.)硬化ヒマシ油 0.3
(3)香料 0.1
(4)精製水 100合わせ
(5)クエン酸 0.02
(6)クエン酸ナトリウム 0.1
(7)グリセリン 1.0
(8)ヒドロキシエチルセルロース 0.1
(9)乳酸菌死菌体 0.05
(10)オリゴ糖 0.1
(11)ニガリ(南大東島産) 1.0
製法:(1)に(2)及び(3)を溶解する。溶解後、(4)〜(8)を順次添加した後、十分に攪拌し、(9)〜(11)を加え、均一に混合する。
[Example 3] Lotion (1) Ethanol 15.0 (% by mass)
(2) Polyoxyethylene (40EO) hydrogenated castor oil 0.3
(3) Fragrance 0.1
(4) 100 sets of purified water (5) Citric acid 0.02
(6) Sodium citrate 0.1
(7) Glycerin 1.0
(8) Hydroxyethyl cellulose 0.1
(9) Lactic acid bacteria dead cells 0.05
(10) Oligosaccharide 0.1
(11) Bittern (from Minamidaitoshima) 1.0
Production method: (2) and (3) are dissolved in (1). After dissolution, (4) to (8) are sequentially added, and then the mixture is sufficiently stirred, and (9) to (11) are added and uniformly mixed.

[実施例4]クリーム
(1)スクワラン 10.0(質量%)
(2)ステアリン酸 2.0
(3)水素添加パーム核油 0.5
(4)水素添加大豆リン脂質 0.1
(5)セタノール 3.6
(6)親油型モノステアリン酸グリセリン 2.0
(7)グリセリン 10.0
(8)パラオキシ安息香酸メチル 0.1
(9)アルギニン(20質量%水溶液) 15.0
(10)精製水 100合わせ
(11)カルボキシビニルポリマー(1質量%水溶液) 15.0
(12)乳酸菌死菌体 0.3
(13)オリゴ糖 0.8
(14)ニガリ 0.5
製法:(1)〜(6)の油相成分を80℃にて加熱溶解する。一方(7)〜(10)の水相成分を80℃にて加熱溶解する。これに前記油相成分を攪拌しながら加え、ホモジナイザーにより均一に乳化する。乳化終了後、(11)を加え、冷却を開始し、40℃にて(12)〜(14)を加え、均一に混合する。
Example 4 Cream (1) Squalane 10.0 (% by mass)
(2) Stearic acid 2.0
(3) Hydrogenated palm kernel oil 0.5
(4) Hydrogenated soybean phospholipid 0.1
(5) Cetanol 3.6
(6) Lipophilic glyceryl monostearate 2.0
(7) Glycerin 10.0
(8) Methyl paraoxybenzoate 0.1
(9) Arginine (20% by mass aqueous solution) 15.0
(10) Purified water 100 combinations (11) Carboxyvinyl polymer (1% by mass aqueous solution) 15.0
(12) Dead lactic acid bacteria 0.3
(13) Oligosaccharide 0.8
(14) Bittern 0.5
Production method: The oil phase components (1) to (6) are dissolved by heating at 80 ° C. On the other hand, the aqueous phase components (7) to (10) are heated and dissolved at 80 ° C. The oil phase component is added thereto with stirring, and the mixture is uniformly emulsified by a homogenizer. After the emulsification is completed, (11) is added, cooling is started, and (12) to (14) are added at 40 ° C. and mixed uniformly.

[実施例5]美容液
(1)精製水 100合わせ(質量%)
(2)グリセリン 10.0
(3)ショ糖脂肪酸エステル 1.3
(4)カルボキシビニルポリマー(1質量%水溶液) 17.5
(5)アルギン酸ナトリウム(1質量%水溶液) 15.0
(6)モノラウリン酸ポリグリセリル 1.0
(7)マカデミアナッツ油脂肪酸フィトステリル 3.0
(8)N-ラウロイル-L-グルタミン酸
ジ(フィトステリル−2−オクチルドデシル) 2.0
(9)硬化パーム油 2.0
(10)スクワラン(オリーブ由来) 1.0
(11)ベヘニルアルコール 0.75
(12)ミツロウ 1.0
(13)ホホバ油 1.0
(14)1、3−ブチレングリコール 10.0
(15)L−アルギニン(10質量%水溶液) 2.0
(16)乳酸菌死菌体 0.4
(17)オリゴ糖 1.0
(18)ニガリ 1.2
製法:(1)〜(6)の水相成分を混合し、75℃にて加熱溶解する。一方、(7)〜(14)の油相成分を混合し、75℃にて加熱溶解する。次いで、上記水相成分に油相成分を添加して予備乳化を行った後、ホモミキサーにて均一に乳化する。乳化終了後に冷却を開始し、50℃にて(15)を加える。さらに40℃まで冷却し、(16)〜(18)を加え、均一に混合する。
[Example 5] Serum (1) 100 purified water (% by mass)
(2) Glycerin 10.0
(3) Sucrose fatty acid ester 1.3
(4) Carboxyvinyl polymer (1% by mass aqueous solution) 17.5
(5) Sodium alginate (1% by mass aqueous solution) 15.0
(6) Polyglyceryl monolaurate 1.0
(7) Macadamia nut oil fatty acid phytosteryl 3.0
(8) N-lauroyl-L-glutamic acid di (phytosteryl-2-octyldodecyl) 2.0
(9) Hardened palm oil 2.0
(10) Squalane (derived from olives) 1.0
(11) Behenyl alcohol 0.75
(12) Beeswax 1.0
(13) Jojoba oil 1.0
(14) 1,3-butylene glycol 10.0
(15) L-arginine (10% by mass aqueous solution) 2.0
(16) Killed cells of lactic acid bacteria 0.4
(17) Oligosaccharide 1.0
(18) Nigari 1.2
Production method: The aqueous phase components (1) to (6) are mixed and heated and dissolved at 75 ° C. On the other hand, the oil phase components (7) to (14) are mixed and heated and dissolved at 75 ° C. Subsequently, after preliminarily emulsifying by adding an oil phase component to the water phase component, the mixture is uniformly emulsified by a homomixer. After completion of the emulsification, cooling is started, and (15) is added at 50 ° C. Further cool to 40 ° C., add (16) to (18), and mix uniformly.

[実施例6]水性ジェル
(1)カルボキシビニルポリマー 0.5(質量%)
(2)精製水 100合わせ
(3)水酸化ナトリウム(10質量%水溶液) 0.5
(4)エタノール 10.0
(5)パラオキシ安息香酸メチル 0.1
(6)香料 0.1
(7)乳酸菌死菌体 0.05
(8)オリゴ糖 0.05
(9)ニガリ(南大東島産) 0.5
(10)ポリオキシエチレン(60E.O.)硬化ヒマシ油 0.1
製法:(1)を(2)に加え、均一に攪拌した後、(3)を加える。均一に攪拌した後、(4)に予め溶解した(5)を加える。均一に攪拌した後、予め混合しておいた(6)〜(10)を加え、均一に攪拌混合する。
Example 6 Aqueous Gel (1) Carboxyvinyl Polymer 0.5 (% by mass)
(2) Purified water 100 combinations (3) Sodium hydroxide (10% by mass aqueous solution) 0.5
(4) Ethanol 10.0
(5) Methyl paraoxybenzoate 0.1
(6) Fragrance 0.1
(7) Lactic acid bacteria dead cells 0.05
(8) Oligosaccharide 0.05
(9) Nigari (from Minamidaitoshima) 0.5
(10) Polyoxyethylene (60EO) hydrogenated castor oil 0.1
Production method: (1) is added to (2), and after stirring uniformly, (3) is added. After stirring uniformly, (5) previously dissolved in (4) is added. After stirring uniformly, (6) to (10) previously mixed are added, and the mixture is stirred and mixed uniformly.

[実施例7]クレンジング料
(1)スクワラン 77.0(質量%)
(2)イソステアリン酸ポリオキシエチレングリセリル 15.0
(3)精製水 100合わせ
(4)乳酸菌死菌体 0.05
(5)オリゴ糖 0.8
(6)ニガリ(南大東島産) 2.0
製法:(1)と(2)を均一に溶解する。これに、(3)〜(6)を順次加え、均一に混合する。
Example 7 Cleansing Charge (1) Squalane 77.0 (% by mass)
(2) Polyoxyethylene glyceryl isostearate 15.0
(3) 100 sets of purified water (4) Killed cells of lactic acid bacteria 0.05
(5) Oligosaccharide 0.8
(6) Bittern (from Minamidaitoshima) 2.0
Production method: (1) and (2) are uniformly dissolved. (3) to (6) are sequentially added thereto, and the mixture is uniformly mixed.

[実施例8]洗顔フォーム
(1)ステアリン酸 16.0(質量%)
(2)ミリスチン酸 16.0
(3)親油型モノステアリン酸グリセリン 2.0
(4)グリセリン 20.0
(5)水酸化ナトリウム 7.5
(6)ヤシ油脂肪酸アミドプロピルベタイン 1.0
(7)精製水 100合わせ
(8)乳酸菌死菌体 0.3
(9)オリゴ糖 0.7
(10)ニガリ 2.5
製法:(1)〜(4)の油相成分を80℃にて加熱溶解する。一方(5)〜(7)の水相成分を80℃にて加熱溶解し、油相成分と均一に混合撹拌する。冷却を開始し、40℃にて(8)〜(10)を加え、均一に混合する。
[Example 8] Facial cleansing foam (1) Stearic acid 16.0 (% by mass)
(2) myristic acid 16.0
(3) Lipophilic glyceryl monostearate 2.0
(4) Glycerin 20.0
(5) Sodium hydroxide 7.5
(6) Coconut oil fatty acid amidopropyl betaine 1.0
(7) 100 pieces of purified water (8) Killed cells of lactic acid bacteria 0.3
(9) Oligosaccharide 0.7
(10) Nigari 2.5
Production method: The oil phase components (1) to (4) are heated and dissolved at 80 ° C. On the other hand, the aqueous phase components (5) to (7) are heated and dissolved at 80 ° C., and uniformly mixed and stirred with the oil phase components. Start cooling, add (8) to (10) at 40 ° C, and mix uniformly.

[実施例9]メイクアップベースクリーム
(1)スクワラン 10.2(質量%)
(2)セタノール 2.0
(3)グリセリントリ−2−エチルヘキサン酸エステル 2.5
(4)親油型モノステアリン酸グリセリル 1.0
(5)プロピレングリコール 11.0
(6)ショ糖脂肪酸エステル 1.3
(7)精製水 100合わせ
(8)酸化チタン 1.0
(9)ベンガラ 0.1
(10)黄酸化鉄 0.4
(11)香料 0.1
(12)乳酸菌死菌体 0.1
(13)オリゴ糖 0.05
(14)ニガリ 0.8
製法:(1)〜(4)の油相成分を混合し、75℃にて加熱溶解する。一方、(5)〜(7)の水相成分を混合し、75℃にて加熱溶解し、これに(8)〜(10)の顔料を加え、ホモミキサーにて均一に分散させる。この水相成分に前記油相成分を加え、ホモミキサーにて乳化する。乳化終了後に冷却を開始し、40℃にて(11)〜(14)の成分を加え、均一に混合する。
Example 9 Makeup Base Cream (1) Squalane 10.2 (% by mass)
(2) Cetanol 2.0
(3) Glycerin tri-2-ethylhexanoate 2.5
(4) Lipophilic glyceryl monostearate 1.0
(5) Propylene glycol 11.0
(6) Sucrose fatty acid ester 1.3
(7) Purified water 100 sets (8) Titanium oxide 1.0
(9) Bengala 0.1
(10) Yellow iron oxide 0.4
(11) Fragrance 0.1
(12) Dead cells of lactic acid bacteria 0.1
(13) Oligosaccharide 0.05
(14) Nigari 0.8
Production method: The oil phase components (1) to (4) are mixed and dissolved by heating at 75 ° C. On the other hand, the aqueous phase components (5) to (7) are mixed and dissolved by heating at 75 ° C., and the pigments (8) to (10) are added thereto and uniformly dispersed by a homomixer. The oil phase component is added to the water phase component and emulsified by a homomixer. After the completion of the emulsification, cooling is started, and the components (11) to (14) are added at 40 ° C. and uniformly mixed.

[実施例10]乳液状ファンデーション
(1)メチルポリシロキサン 2.0(質量%)
(2)スクワラン 5.0
(3)ミリスチン酸オクチルドデシル 5.0
(4)セタノール 1.0
(5)ポリオキシエチレン(20E.O.)
ソルビタンモノステアリン酸エステル 1.3
(6)モノステアリン酸ソルビタン 0.7
(7)1、3−ブチレングリコール 8.0
(8)キサンタンガム 0.1
(9)パラオキシ安息香酸メチル 0.1
(10)精製水 100合わせ
(11)酸化チタン 9.0
(12)タルク 7.4
(13)ベンガラ 0.5
(14)黄酸化鉄 1.1
(15)黒酸化鉄 0.1
(16)香料 0.1
(17)乳酸菌死菌体 0.05
(18)オリゴ糖 0.1
(19)ニガリ(南大東島産) 1.0
製法:(1)〜(6)の油相成分を混合し、75℃にて加熱溶解する。一方、(7)〜(10)の水相成分を混合し、75℃にて加熱溶解し、これに(11)〜(15)の顔料を加え、ホモミキサーにて均一に分散する。油相成分を加え、乳化を行う。乳化終了後に冷却を開始し、40℃にて(16)〜(19)の成分を順次加え、均一に混合する。
Example 10 Emulsion Foundation (1) Methylpolysiloxane 2.0 (% by mass)
(2) Squalane 5.0
(3) Octyldodecyl myristate 5.0
(4) Cetanol 1.0
(5) Polyoxyethylene (20EO)
Sorbitan monostearate 1.3
(6) Sorbitan monostearate 0.7
(7) 1,3-butylene glycol 8.0
(8) Xanthan gum 0.1
(9) Methyl paraoxybenzoate 0.1
(10) Purified water 100 sets (11) Titanium oxide 9.0
(12) Talc 7.4
(13) Bengala 0.5
(14) Yellow iron oxide 1.1
(15) Black iron oxide 0.1
(16) Fragrance 0.1
(17) Killed cells of lactic acid bacteria 0.05
(18) Oligosaccharide 0.1
(19) Nigari (from Minamidaitoshima) 1.0
Production method: The oil phase components (1) to (6) are mixed and dissolved by heating at 75 ° C. On the other hand, the aqueous phase components (7) to (10) are mixed and dissolved by heating at 75 ° C., and the pigments (11) to (15) are added thereto and uniformly dispersed by a homomixer. Add oil phase components and emulsify. After the completion of the emulsification, cooling is started, and the components (16) to (19) are sequentially added at 40 ° C. and uniformly mixed.

[実施例11]油中水型エモリエントクリーム
(1)流動パラフィン 30.0(質量%)
(2)マイクロクリスタリンワックス 2.0
(3)ワセリン 5.0
(4)ジグリセリンオレイン酸エステル 5.0
(5)ニガリ 1.4
(6)プロピレングリコール 3.0
(7)1、3−ブチレングリコール 5.0
(8)パラオキシ安息香酸メチル 0.1
(9)乳酸菌死菌体 0.5
(10)オリゴ糖 0.8
(11)精製水 100合わせ
(12)香料 0.1
製法:(5)を(11)の一部に溶解して50℃とし、50℃に加熱した(4)に撹拌しながら徐々に加える。これを混合した後、70℃にて加熱溶解した(1)〜(3)に均一に分散する。これに(6)〜(10)を(11)の残部に70℃にて加熱溶解したものを撹拌しながら加え、ホモミキサーにて乳化する。乳化終了後に冷却を開始し、40℃にて(12)を加え、均一に混合する。
[Example 11] Water-in-oil type emollient cream (1) Liquid paraffin 30.0 (% by mass)
(2) Microcrystalline wax 2.0
(3) Vaseline 5.0
(4) Diglycerin oleate 5.0
(5) Nigari 1.4
(6) Propylene glycol 3.0
(7) 1,3-butylene glycol 5.0
(8) Methyl paraoxybenzoate 0.1
(9) Killed lactic acid bacteria 0.5
(10) Oligosaccharide 0.8
(11) Purified water 100 sets (12) Fragrance 0.1
Production method: (5) is dissolved in a part of (11) to 50 ° C., and gradually added to (4) heated to 50 ° C. with stirring. After mixing, the mixture is heated and dissolved at 70 ° C. and uniformly dispersed in (1) to (3). A mixture obtained by heating and dissolving (6) to (10) in the remainder of (11) at 70 ° C. is added thereto with stirring, and emulsified by a homomixer. After completion of the emulsification, cooling is started, (12) is added at 40 ° C., and the mixture is uniformly mixed.

[実施例12]パック
(1)精製水 100合わせ(質量%)
(2)ポリビニルアルコール 12.0
(3)エタノール 17.0
(4)グリセリン 5.0
(5)ポリエチレングリコール(平均分子量1000) 2.0
(6)乳酸菌死菌体 0.08
(7)オリゴ糖 1.0
(8)ニガリ(南大東島産) 0.5
(9)香料 0.1
製法:(2)と(3)を混合し、80℃に加温した後、80℃に加温した(1)に溶解する。均一に溶解した後、(4)と(5)を加え、攪拌しながら冷却を開始する。40℃まで冷却し、(6)〜(9)を加え、均一に混合する。
[Example 12] Pack (1) 100 purified water (% by mass)
(2) Polyvinyl alcohol 12.0
(3) Ethanol 17.0
(4) Glycerin 5.0
(5) polyethylene glycol (average molecular weight 1000) 2.0
(6) Killed cells of lactic acid bacteria 0.08
(7) Oligosaccharide 1.0
(8) Bittern (from Minamidaitoshima) 0.5
(9) Fragrance 0.1
Production method: (2) and (3) are mixed, heated to 80 ° C., and dissolved in (1) heated to 80 ° C. After uniform dissolution, (4) and (5) are added, and cooling is started with stirring. Cool to 40 ° C., add (6) to (9), and mix uniformly.

Claims (1)

下記(A)〜(C)を含有する皮膚外用剤。
(A)乳酸菌死菌体
(B)オリゴ糖
(C)ニガリ
An external preparation for skin containing the following (A) to (C).
(A) Dead cells of lactic acid bacteria (B) Oligosaccharides (C) Bittern
JP2018165621A 2018-09-05 2018-09-05 Skin topical agent Active JP7130330B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2018165621A JP7130330B2 (en) 2018-09-05 2018-09-05 Skin topical agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2018165621A JP7130330B2 (en) 2018-09-05 2018-09-05 Skin topical agent

Publications (2)

Publication Number Publication Date
JP2020037533A true JP2020037533A (en) 2020-03-12
JP7130330B2 JP7130330B2 (en) 2022-09-05

Family

ID=69737532

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018165621A Active JP7130330B2 (en) 2018-09-05 2018-09-05 Skin topical agent

Country Status (1)

Country Link
JP (1) JP7130330B2 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005139075A (en) * 2003-11-04 2005-06-02 Noevir Co Ltd Agent for controlling balance of ecosystem of indigenous bacterium in skin
JP2007153800A (en) * 2005-12-05 2007-06-21 Noevir Co Ltd Agent for adjusting ecological balance of indigenous bacterium in skin
JP2017101006A (en) * 2015-12-04 2017-06-08 一丸ファルコス株式会社 Glycerol production enhancer derived from staphylococcus-epidermidis, antimicrobial peptide production enhancer derived from skin epidermal keratinocyte, and their application to external preparations for skin protection
WO2017196006A1 (en) * 2016-05-10 2017-11-16 Haudongchun Co., Ltd A composition comprising a lactic acid bacteria for preventing and treating vaginosis and the use thereof
JP2017534589A (en) * 2014-09-23 2017-11-24 コリア インスティテュート オブ オリエンタル メディシン Skin moisturizing or wrinkle-improving composition comprising tyndalized lactic acid bacteria killed as an active ingredient

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005139075A (en) * 2003-11-04 2005-06-02 Noevir Co Ltd Agent for controlling balance of ecosystem of indigenous bacterium in skin
JP2007153800A (en) * 2005-12-05 2007-06-21 Noevir Co Ltd Agent for adjusting ecological balance of indigenous bacterium in skin
JP2017534589A (en) * 2014-09-23 2017-11-24 コリア インスティテュート オブ オリエンタル メディシン Skin moisturizing or wrinkle-improving composition comprising tyndalized lactic acid bacteria killed as an active ingredient
JP2017101006A (en) * 2015-12-04 2017-06-08 一丸ファルコス株式会社 Glycerol production enhancer derived from staphylococcus-epidermidis, antimicrobial peptide production enhancer derived from skin epidermal keratinocyte, and their application to external preparations for skin protection
WO2017196006A1 (en) * 2016-05-10 2017-11-16 Haudongchun Co., Ltd A composition comprising a lactic acid bacteria for preventing and treating vaginosis and the use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
月田信太郎: "皮膚粘膜障害改善のためのサプリメント 東洋酵素化学とE&Cが共同開発", 食品工業, JPN6021047487, 15 June 2012 (2012-06-15), pages 70 - 73, ISSN: 0004649226 *

Also Published As

Publication number Publication date
JP7130330B2 (en) 2022-09-05

Similar Documents

Publication Publication Date Title
US10238597B2 (en) Probiotic treatment of skin diseases, disorders, and infections: formulations, methods and systems
TWI586373B (en) Cosmetic composition containing biocellulose film fragments and method for manufacturing thereof
JP4116243B2 (en) Skin composition
JP4644589B2 (en) Negative ion water production method and negative ion water
JPH01305012A (en) Skin humidifying composition and production thereof
CN103476390B (en) Emulsion oil-in-water compositions and production method thereof
CN110638707A (en) Eye care cream and preparation method thereof
KR20180138399A (en) Inhibitor for NO activator, Anit-inflammation agent containing of the same, Revitalizing cosmetics containing the same and Manufacturing method thereof
CN105267085A (en) Skin-beautifying facial cleanser and preparation method thereof
CN107982086A (en) One kind makeup removing gel and preparation method thereof
JP2002053429A (en) Use of cubic gel particle as anti-pollution agent, especially in cosmetic
CN114557902A (en) Oil-based gel capable of suspending particles, all-oil system bath gel and preparation method thereof
CN106580758B (en) A kind of oil-control water-setting cream and preparation method thereof
KR20140110168A (en) Cosmetic composition for improving acne
JP7130330B2 (en) Skin topical agent
JPH10287540A (en) Moisture-retaining agent
JP2012246324A (en) External skin care preparation
JP2007055926A (en) Humectant
JP3881323B2 (en) External preparation composition
JPH04321615A (en) Skin medicine for external use
CN112494392A (en) Clean oil-in-water cosmetic composition and preparation method thereof
JP2004097999A (en) Emulsifier and cosmetic
JP2003231626A (en) Atp production promoter
JP3739971B2 (en) Composition for external use
JP3556479B2 (en) Skin pre-treatment agent

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210304

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211130

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220607

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220805

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220823

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220823

R150 Certificate of patent or registration of utility model

Ref document number: 7130330

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150